RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Amos Sakwe to Antineoplastic Agents

This is a "connection" page, showing publications Amos Sakwe has written about Antineoplastic Agents.
Connection Strength

0.886
  1. Vuong NB, Korolkova OY, Izban MG, Sakwe NI, McIntosh AR, Ball DD, Black PJ, Edwards AD, Ballard BR, Adunyah SE, Sakwe AM. Contribution of Mesenchymal-like and Epithelial Cellular Subsets to Chemotherapy Resistance in Triple-Negative Breast Cancer. Int J Mol Sci. 2026 Mar 31; 27(7).
    View in: PubMed
    Score: 0.529
  2. Koumangoye RB, Nangami GN, Thompson PD, Agboto VK, Ochieng J, Sakwe AM. Reduced annexin A6 expression promotes the degradation of activated epidermal growth factor receptor and sensitizes invasive breast cancer cells to EGFR-targeted tyrosine kinase inhibitors. Mol Cancer. 2013 Dec 19; 12(1):167.
    View in: PubMed
    Score: 0.226
  3. Gonzalez SB, Shivam P, Ball D, Ajisegiri SB, Osi I, Misra S, Mutchler AL, Lindsey ML, Martin PM, Sakwe AM, Nde PN. Bugs as drugs: parasite biomolecules as novel therapeutics against breast cancer. Am J Physiol Cell Physiol. 2026 Apr 01; 330(4):C1067-C1080.
    View in: PubMed
    Score: 0.132
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support